Targeting ageing with rapamycin and its derivatives in humans: a systematic review
- PMID: 38310895
- DOI: 10.1016/S2666-7568(23)00258-1
Targeting ageing with rapamycin and its derivatives in humans: a systematic review
Abstract
Rapamycin and its derivatives (rapalogs) are inhibitors of mTOR, a major regulator of the ageing process. We aimed to summarise the effects of rapamycin and its derivatives on the severity of ageing-related physiological changes and disease in adults. A search across five databases yielded 18 400 unique articles, resulting in 19 included studies. Rapamycin and its derivatives improved physiological parameters associated with ageing in the immune, cardiovascular, and integumentary systems of healthy individuals or individuals with ageing-related diseases. Overall, no significant effects on the endocrine, muscular, or neurological systems were found. The effects of rapamycin or its derivatives on the respiratory, digestive, renal, and reproductive systems were not assessed. No serious adverse events attributed to rapamycin and its derivatives were reported in healthy individuals; however, there were increased numbers of infections and increases in total cholesterol, LDL cholesterol, and triglycerides in individuals with ageing-related diseases. Future studies should assess the remaining unexamined systems and test the effects of long-term exposure to rapamycin and its derivatives.
Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests We declare no competing interests.
Similar articles
-
Rapamycin and rapalogs for tuberous sclerosis complex.Cochrane Database Syst Rev. 2016 Jul 13;7(7):CD011272. doi: 10.1002/14651858.CD011272.pub2. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2023 Jul 11;7:CD011272. doi: 10.1002/14651858.CD011272.pub3 PMID: 27409709 Free PMC article. Updated. Review.
-
The Role of Rapamycin in Healthspan Extension via the Delay of Organ Aging.Ageing Res Rev. 2021 Sep;70:101376. doi: 10.1016/j.arr.2021.101376. Epub 2021 Jun 2. Ageing Res Rev. 2021. PMID: 34089901 Review.
-
Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor.Aging Cell. 2023 Aug;22(8):e13888. doi: 10.1111/acel.13888. Epub 2023 May 24. Aging Cell. 2023. PMID: 37222020 Free PMC article.
-
Blazing a trail for the clinical use of rapamycin as a geroprotecTOR.Geroscience. 2023 Oct;45(5):2769-2783. doi: 10.1007/s11357-023-00935-x. Epub 2023 Oct 6. Geroscience. 2023. PMID: 37801202 Free PMC article.
-
Rapalogs and mTOR inhibitors as anti-aging therapeutics.J Clin Invest. 2013 Mar;123(3):980-9. doi: 10.1172/JCI64099. Epub 2013 Mar 1. J Clin Invest. 2013. PMID: 23454761 Free PMC article. Review.
Cited by
-
Gut aging: A wane from the normal to repercussion and gerotherapeutic strategies.Heliyon. 2024 Sep 12;10(19):e37883. doi: 10.1016/j.heliyon.2024.e37883. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39381110 Free PMC article. Review.
-
mTOR inhibitors potentially preserve fertility in female patients with haematopoietic malignancies: a narrative review.Ann Hematol. 2024 Dec;103(12):4953-4969. doi: 10.1007/s00277-024-06090-3. Epub 2024 Nov 13. Ann Hematol. 2024. PMID: 39537993 Review.
-
The brain-body energy conservation model of aging.Nat Aging. 2024 Oct;4(10):1354-1371. doi: 10.1038/s43587-024-00716-x. Epub 2024 Oct 8. Nat Aging. 2024. PMID: 39379694 Review.
-
Sex-specific molecular signature of mouse podocytes in homeostasis and in response to pharmacological challenge with rapamycin.Biol Sex Differ. 2024 Sep 15;15(1):72. doi: 10.1186/s13293-024-00647-7. Biol Sex Differ. 2024. PMID: 39278930 Free PMC article.
-
Mifepristone and rapamycin have non-additive benefits for life span in mated female Drosophila.Fly (Austin). 2024 Dec;18(1):2419151. doi: 10.1080/19336934.2024.2419151. Epub 2024 Oct 23. Fly (Austin). 2024. PMID: 39440794 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous